{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:37:20Z","timestamp":1791041840082,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.dmpk.2025.101512","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:00:12Z","timestamp":1765526412000},"page":"101512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Future directions in drug-drug interaction evaluations: Industry perspective on the ICH M12 guidance"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-3430","authenticated-orcid":false,"given":"Kenichi","family":"Umehara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5403-5722","authenticated-orcid":false,"given":"Andrew","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8662-3054","authenticated-orcid":false,"given":"Chandra","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Eric","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5385-0223","authenticated-orcid":false,"given":"Justine","family":"Bad\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8638-5751","authenticated-orcid":false,"given":"Manoli","family":"Vourvahis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5696-7601","authenticated-orcid":false,"given":"Natasa","family":"Pajkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-7714","authenticated-orcid":false,"given":"Neil","family":"Parrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Marroum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Laethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2025.101512_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt.3625","article-title":"ICH M12 drug interaction studies: summary of the efforts to achieve global convergence","volume":"118","author":"Reynolds","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1124\/dmd.108.020834","article-title":"Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data","volume":"36","author":"Kilford","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib3","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib4","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1016\/j.xphs.2017.09.005","article-title":"Industry perspective on contemporary protein-binding methodologies: considerations for regulatory drug-drug interaction and related guidelines on highly bound drugs","volume":"106","author":"Di","year":"2017","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.dmpk.2025.101512_bib5","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1016\/j.xphs.2019.08.004","article-title":"Applying two orthogonal methods to assess accuracy of plasma protein binding measurements for highly bound compounds","volume":"108","author":"Ryu","year":"2019","journal-title":"J Pharmacol Sci"},{"issue":"116","key":"10.1016\/j.dmpk.2025.101512_bib6","article-title":"Considerations from the IQ induction working group in response to drug-drug interaction guidances from regulatory agencies: focus on down-regulation, CYP2C induction and CYP2B6 positive control","volume":"45","author":"Hariparsad","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158674","article-title":"Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro","volume":"11","author":"Nguyen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.dmpk.2025.101512_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5516","article-title":"Reproducing human and cross-species drug toxicities using a liver-chip","volume":"11","author":"Jang","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.dmpk.2025.101512_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/srep25187","article-title":"Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease","volume":"6","author":"Bell","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.dmpk.2025.101512_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201800347","article-title":"3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications","volume":"14","author":"Lauschke","year":"2019","journal-title":"Biotechnol J"},{"key":"10.1016\/j.dmpk.2025.101512_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2022.105504","article-title":"The morphology, functionality, and longevity of a novel all human hepatic cell-based tri-culture system","volume":"86","author":"Weaver","year":"2023","journal-title":"Toxicol Vitro"},{"key":"10.1016\/j.dmpk.2025.101512_bib12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/cpt.1860","article-title":"Clinically relevant cytochrome P450 3A4 induction mechanisms and drug screening in three\u2010dimensional spheroid cultures of primary human hepatocytes","volume":"108","author":"Hendriks","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib13","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/cpt.2887","article-title":"3D spheroid primary human hepatocytes for prediction of cytochrome P450 and drug transporter induction","volume":"113","author":"J\u00e4rvinen","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2023.100886","article-title":"Characterization of a novel human hepatocyte model, truvivoTM for the projection of clinical induction of drug metabolizing enzymes","volume":"55","author":"Slavsky","year":"2024","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.dmpk.2025.101512_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100052","article-title":"Quantitative clinical risk assessment of CYP2C, UDP-glucuronosyltransferase, P-glycoprotein induction, and complex drug-drug interactions using TruVivo human hepatocyte triculture platform","volume":"53","author":"Ramsden","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib16","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000204890","article-title":"Soticlestat in vitro metabolism and drug-drug interactions: comprehensive investigations display minimal notable interactions (P9-1.012)","volume":"102","author":"Cohen","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.dmpk.2025.101512_bib17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/bcp.15917","article-title":"Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24\u2010hydroxylase inhibitor soticlestat in healthy volunteers","volume":"90","author":"Yin","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/00498254.2025.2532649","article-title":"Comprehensive in vitro assessment of drug-drug interactions of the major human metabolite of soticlestat","volume":"55","author":"Ugajin","year":"2025","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2025.101512_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/cpt.2259","article-title":"Do inhibitory metabolites impact DDI risk assessment? Analysis of in vitro and in vivo data from NDA reviews between 2013 and 2018","volume":"110","author":"Steinbronn","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0920-1211(00)00160-1","article-title":"Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy","volume":"42","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.dmpk.2025.101512_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0006-2952(92)90303-Z","article-title":"In vitro inhibition studies of the glucuronidation of 3\u2032-azido-3\u2032-deoxythymidine catalysed by human liver UDP-Glucuronosyl transferase","volume":"43","author":"Macleod","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/clpt.2011.36","article-title":"Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects","volume":"89","author":"Kusuhara","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib23","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/mol.109.056242","article-title":"Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion of metformin","volume":"75","author":"Tsuda","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejps.2016.03.020","article-title":"Metformin and cimetidine: physiologically based pharmacokinetic modelling to investigate transporter mediated drug\u2013drug interactions","volume":"88","author":"Burt","year":"2016","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.dmpk.2025.101512_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.357","volume":"5","author":"Elsby","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.dmpk.2025.101512_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.dmpk.2025.101512_bib27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","article-title":"Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug\u2013drug interaction studies","volume":"59","author":"Elmeliegy","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2025.101512_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/00498254.2014.955831","article-title":"Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture","volume":"45","author":"Badolo","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2025.101512_bib30","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/psp4.12717","article-title":"Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: assessing the induction magnitude of P\u2010glycoprotein\u2013cytochrome P450 3A4 dual substrates","volume":"10","author":"Pan","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib31","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/jnc.13389","article-title":"In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator\u2010activated receptor alpha (Ppar\u03b1) at the blood\u2013brain barrier","volume":"135","author":"Hoque","year":"2015","journal-title":"J Neurochem"},{"key":"10.1016\/j.dmpk.2025.101512_bib32","doi-asserted-by":"crossref","first-page":"E798","DOI":"10.1152\/ajpendo.00397.2005","article-title":"Regulation of BCRP\/ABCG2 expression by progesterone and 17\u03b2-estradiol in human placental BeWo cells","volume":"290","author":"Wang","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.dmpk.2025.101512_bib33","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1471-4159.2008.05537.x","article-title":"Activation of \u03b2\u2010catenin signalling by GSK\u20103 inhibition increases p\u2010glycoprotein expression in brain endothelial cells","volume":"106","author":"Lim","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.dmpk.2025.101512_bib34","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/cas.12223","article-title":"Inhibition of Wnt\/\u03b2\u2010catenin signaling downregulates p\u2010glycoprotein and reverses multi\u2010drug resistance of cholangiocarcinoma","volume":"104","author":"Shen","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.dmpk.2025.101512_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/jpet.120.000139","article-title":"Absence of OATP1B (organic anion\u2013transporting polypeptide) induction by Rifampin in cynomolgus monkeys: determination using the endogenous OATP1B marker coproporphyrin and tissue gene expression","volume":"375","author":"Zhang","year":"2020","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.dmpk.2025.101512_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.119.089615","article-title":"Induction of human intestinal and hepatic organic anion transporting polypeptides: where is the evidence for its relevance in drug-drug interactions?","volume":"48","author":"David","year":"2020","journal-title":"Drug Metabol Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/cpt.2605","article-title":"Regulation of drug transport proteins\u2014from mechanisms to clinical impact: a white paper on behalf of the international transporter consortium","volume":"112","author":"Brouwer","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2024.143474","article-title":"Induction of drug metabolizing enzyme and drug transporter expression by antifungal triazole pesticides in human HepaSH hepatocytes","volume":"366","author":"Zerdoug","year":"2024","journal-title":"Chemosphere"},{"key":"10.1016\/j.dmpk.2025.101512_bib39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1208\/s12248-008-9019-6","article-title":"Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates","volume":"10","author":"Harper","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.dmpk.2025.101512_bib40","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct OF IN vitro and IN VIVO drug-drug interaction studies: a PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib41","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/bdd.760","article-title":"Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter\u2010system extrapolation factors","volume":"32","author":"Crewe","year":"2011","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/dmd.121.000758","article-title":"Intersystem extrapolation factors are substrate-dependent for CYP3A4: impact on cytochrome P450 reaction phenotyping","volume":"50","author":"Dantonio","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib43","first-page":"191","article-title":"Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) \u2013 a comparison with the chemical inhibition method","volume":"32","author":"Umehara","year":"2017","journal-title":"Drug Metab Pers Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.3686","article-title":"Prospective DDI risk assessment of vicasinabin with PBPK modeling by integrating in vitro data","author":"Umehara","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib45","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/2472555219831407","article-title":"Application of new cellular and microphysiological systems to drug metabolism optimization and their positioning respective to in silico tools","volume":"24","author":"Docci","year":"2019","journal-title":"SLAS Discov"},{"key":"10.1016\/j.dmpk.2025.101512_bib46","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/dmd.120.000133","article-title":"Application of the extended clearance classification system (ECCS) in drug discovery and development: selection of appropriate in vitro tools and clearance prediction","volume":"48","author":"Umehara","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib47","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1021\/acs.molpharmaceut.6b00396","article-title":"Use of H\u03bcREL human coculture system for prediction of intrinsic clearance and metabolite formation for slowly metabolized compounds","volume":"13","author":"Hultman","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmpk.2025.101512_bib48","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.120.000340","article-title":"Primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low hepatic clearance","volume":"49","author":"Riede","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1208\/s12248-022-00689-y","article-title":"Multi-well array culture of primary human hepatocyte spheroids for clearance extrapolation of slowly metabolized compounds","volume":"24","author":"Preiss","year":"2022","journal-title":"AAPS J"},{"key":"10.1016\/j.dmpk.2025.101512_bib50","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1124\/dmd.113.053397","article-title":"Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac","volume":"41","author":"Chan","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib51","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.121.000765","article-title":"Estimation of fraction metabolized by cytochrome P450 enzymes using long-term cocultured human hepatocytes","volume":"50","author":"Klammers","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib52","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1124\/dmd.121.000601","article-title":"Reaction phenotyping of low-turnover compounds in long-term hepatocyte cultures through persistent selective inhibition of cytochromes P450","volume":"49","author":"Smith","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib53","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.115.067876","article-title":"Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method","volume":"44","author":"Yang","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib54","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/pharmaceutics17040531","article-title":"Matrix approach assessment of cabotegravir drug\u2013drug interactions with OAT1\/OAT3 substrates and UGT1A1\/UGT1A9 inhibitors using physiologically-based pharmacokinetic modeling","volume":"17","author":"Tracey","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.dmpk.2025.101512_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/psp4.12581","article-title":"Physiologically\u2010based pharmacokinetic modeling of the drug\u2013drug interaction of the UGT substrate ertugliflozin following co\u2010administration with the UGT inhibitor mefenamic acid","volume":"10","author":"Callegari","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/dmd.123.001487","article-title":"Physiologically-based pharmacokinetic modeling for drugs cleared by non-cytochrome P450 enzymes: state-of-the-Art and future perspectives","volume":"52","author":"Ozbey","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib57","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s11095-024-03750-x","article-title":"Comparison of relative activity versus relative expression factors (RAF versus REF) in predicting glucuronidation mediated drug clearance using recombinant UGTs","volume":"41","author":"Subash","year":"2024","journal-title":"Pharm Res"},{"key":"10.1016\/j.dmpk.2025.101512_bib58","first-page":"150","article-title":"Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects","volume":"50","author":"Tran","year":"2019","journal-title":"Xenobiotica; the Fate of Foreign Compounds in Biological Systems"},{"key":"10.1016\/j.dmpk.2025.101512_bib59","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/cpt.1693","article-title":"Physiologically\u2010based pharmacokinetic models for evaluating membrane transporter mediated drug\u2013drug interactions: current capabilities, case studies, future opportunities, and recommendations","volume":"107","author":"Taskar","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108271","article-title":"The next frontier in ADME science: predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans","volume":"238","author":"Storelli","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib61","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1021\/acs.molpharmaceut.8b00138","article-title":"Relative activity factor (RAF)-based scaling of uptake clearance mediated by organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes","volume":"15","author":"Izumi","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmpk.2025.101512_bib62","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cpt.2713","article-title":"Reimagining the framework supporting the static analysis of transporter drug interaction risk; integrated use of biomarkers to generate pan\u2010transporter inhibition signatures","volume":"113","author":"Rodrigues","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib63","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/03602532.2016.1239630","article-title":"Perspective: 4\u03b2-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A","volume":"49","author":"Mao","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmpk.2025.101512_bib64","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1124\/dmd.124.001680","article-title":"1\u03b2-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of CYP3A clinical drug\u2013drug interaction potential","volume":"52","author":"Xue","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib65","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dmpk.2025.101512_bib66","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/cpt.3062","article-title":"Utilization of OATP1B biomarker coproporphyrin\u2010I to guide drug\u2013drug interaction risk assessment: evaluation by the pharmaceutical industry","volume":"114","author":"Kikuchi","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib67","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1002\/jcph.723","article-title":"Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1","volume":"56","author":"Vaidyanathan","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib68","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cpt.1599","article-title":"Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI","volume":"107","author":"Jones","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib69","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cpt.3399","article-title":"Coproporphyrin\u2010I as a selective OATP1B biomarker can be used to delineate the mechanisms of complex drug\u2013drug interactions: cedirogant case study","volume":"116","author":"Kikuchi","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib70","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cpt.3477","article-title":"Building confidence in physiologically based pharmacokinetic modeling of CYP3A induction mediated by rifampin: an industry perspective","volume":"117","author":"Reddy","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib71","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","article-title":"DRUG-DRUG interaction between pitavastatin and various drugs via OATP1B1","volume":"34","author":"Hirano","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib72","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/cpt.2584","article-title":"Effect of cyclosporin A and impact of dose staggering on OATP1B1\/1B3 endogenous substrates and drug probes for assessing clinical drug interactions","volume":"111","author":"Mochizuki","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib73","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/cpt.3564","article-title":"Navigating the challenges of cyclosporine as an alternative to rifampicin as an OATP1B index inhibitor","volume":"117","author":"Varma","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib74","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1158\/1078-0432.CCR-04-1725","article-title":"Cyclosporin A is a broad-spectrum multidrug resistance modulator","volume":"11","author":"Qadir","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dmpk.2025.101512_bib75","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/dmd.111.043018","article-title":"Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro","volume":"40","author":"Amundsen","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib76","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/clinchem\/34.10.2012","article-title":"Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic, and bone-marrow transplants","volume":"34","author":"Clardy","year":"1988","journal-title":"Clin Chem"},{"key":"10.1016\/j.dmpk.2025.101512_bib77","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cpt.1695","article-title":"Dose\u2010dependent inhibition of OATP1B by rifampicin in healthy volunteers: comprehensive evaluation of candidate biomarkers and OATP1B probe drugs","volume":"107","author":"Mori","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib78","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/cpt.2402","article-title":"Physiologically based pharmacokinetic modelling to investigate the impact of the cytokine storm on CYP3A drug pharmacokinetics in COVID\u201019 patients","volume":"111","author":"Stader","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib79","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/psp4.12730","article-title":"Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics","volume":"11","author":"Lenoir","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib80","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/psp4.13073","article-title":"Assessment of CYP3A\u2010mediated drug interaction via cytokine (IL\u20106) elevation for mosunetuzumab using physiologically\u2010based pharmacokinetic modeling","volume":"13","author":"Chen","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib81","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/psp4.13144","article-title":"Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: a case study of teclistamab","volume":"13","author":"Willemin","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib82","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/psp4.13091","article-title":"Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL\u20106 levels following administration of the T\u2010cell bispecific engager glofitamab","volume":"13","author":"Djebli","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib83","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1124\/dmd.122.000926","article-title":"Physiologically based pharmacokinetic modeling to predict drug-biologic interactions with cytokine modulators: are these relevant and is Interleukin-6 enough?","volume":"50","author":"Chen","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib84","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/cts.13164","article-title":"Utilization of physiologically\u2010based pharmacokinetic model to assess disease\u2010mediated therapeutic protein\u2010disease\u2010drug interaction in immune\u2010mediated inflammatory diseases","volume":"15","author":"Wang","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.dmpk.2025.101512_bib85","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.111.038679","article-title":"Effects of Interleukin-6 (IL-6) and an Anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture","volume":"39","author":"Dickmann","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib86","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/psp4.13185","article-title":"Is PBPK useful to inform product label on managing clinically significant drug interactions mediated by cytokine release syndrome?","volume":"13","author":"Zhang","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib87","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/cpt.3560","article-title":"Cytokine dynamics in action: a mechanistic approach to assess interleukin 6 related therapeutic Protein\u2010Drug\u2013Disease interactions","volume":"117","author":"Pan","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib88","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1002\/jcph.1718","article-title":"Physiologically based pharmacokinetic model\u2010informed drug development for polatuzumab vedotin: label for drug\u2010drug interactions without dedicated clinical trials","volume":"60","author":"Samineni","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70088","article-title":"PBPK modeling to predict clinical drug\u2013drug interaction and impact of hepatic impairment for an ADC with the payload Auristatin f\u2010hydroxypropylamide","author":"Kumar","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101512_bib90","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/cpt.2448","article-title":"Risk\u2010based pharmacokinetic and drug\u2013drug interaction characterization of antibody\u2013drug conjugates in oncology clinical development: an international consortium for innovation and quality in pharmaceutical development perspective","volume":"112","author":"Li","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib91","series-title":"NUMBER: 22-512 chemistry review(S)","year":"2010"},{"key":"10.1016\/j.dmpk.2025.101512_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2022.100479","article-title":"Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation","volume":"47","author":"Laizure","year":"2022","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.dmpk.2025.101512_bib93","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/dmd.113.054353","article-title":"Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis","volume":"42","author":"Laizure","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib94","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1021\/acs.molpharmaceut.9b00472","article-title":"Renal excretion of dabigatran: the potential role of multidrug and toxin extrusion (MATE) proteins","volume":"16","author":"Shen","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmpk.2025.101512_bib95","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/cpt.525","article-title":"Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A","volume":"101","author":"Prueksaritanont","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101512_bib96","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib97","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1124\/dmd.123.001353","article-title":"The potentially significant role of CYP3A-Mediated oxidative metabolism of dabigatran etexilate and its intermediate metabolites in drug-drug interaction assessments using microdose dabigatran etexilate","volume":"51","author":"Udomnilobol","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101512_bib98","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","article-title":"Enterohepatic circulation: physiological, pharmacokinetic and clinical implications","volume":"41","author":"Roberts","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2025.101512_bib99","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1038\/s41598-021-85174-w","article-title":"Enteric reabsorption processes and their impact on drug pharmacokinetics","volume":"11","author":"Ibarra","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.dmpk.2025.101512_bib100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.drudis.2013.11.020","article-title":"Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics","volume":"19","author":"Gao","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.dmpk.2025.101512_bib101","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1103","article-title":"Oral antibiotics lower mycophenolate mofetil drug exposure, possibly by interfering with the enterohepatic recirculation: a case series","volume":"11","author":"Simoons","year":"2023","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.dmpk.2025.101512_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5914","article-title":"Sustained suppression of enterohepatic circulation of mycophenolic acid by antimicrobial\u2010associated diarrhea in a kidney transplant recipient with Crohn's disease: a case report","volume":"10","author":"Tanaka","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.dmpk.2025.101512_bib103","first-page":"599","article-title":"Exploring antibiotic-mediated disruption of enterohepatic circulation and combined oral contraceptive efficacy: a systematic review","volume":"6","author":"Elkhoury","year":"2025","journal-title":"Women\u2019s Heal Rep"},{"key":"10.1016\/j.dmpk.2025.101512_bib104","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cpt.3436","article-title":"Utility of biomarker\u2010informed drug interaction evaluation in drug development and regulatory decision making","volume":"117","author":"Ishiguro","year":"2025","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436725004628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436725004628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:13:02Z","timestamp":1774624382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436725004628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":104,"alternative-id":["S1347436725004628"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2025.101512","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future directions in drug-drug interaction evaluations: Industry perspective on the ICH M12 guidance","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2025.101512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101512"}}